ClinicalTrials.gg
Active, not recruitingNCT06125977Updated Dec 17, 2025

Impact of Non-Exudative Type 1 MNV on AMD Progression

An observational study in Age-Related Macular Degeneration and Neovascularization, Choroidal, sponsored by University of Utah. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by University of Utah · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
73
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
96th of 146
73 · median 100
Started
2023
with 23 others
Observational
146 of 645
25 open now
Primary completion
2027-08
later than 63 of 124 live
Registered
534th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 96th largest by enrollment of the 146 observational ones that give a count, is one of 24 that started in 2023, is one of 146 observational ones, reaches primary completion later than 63 of the 124 other live ones, and was the 534th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The overall goal of the proposed research project is to provide evidence that a specific subtype of neovascularization that may develop in eyes with age-related macular degeneration (AMD) prevents vision loss.

This concept challenges the current view that the development of neovascularizations in AMD represents a harmful event in general. Notably, before the era of anti-vascular endothelial growths factor (VEGF) therapy, destruction and surgical removal of neovascular membranes have been tested as treatment options for neovascular AMD.

This research project aims to substantiate the hypothesis that type 1 macular neovascularization (MNV) is intrinsically protective, in sense of a positive response to the degenerative processes in AMD. This concept has actually been proposed by pathologists decades ago but has not been systematically investigated in vivo.

With the immense advances in retinal imaging, 'sub-clinical', non-exudative type 1 MNVs that are located beneath the retinal pigment epithelium (RPE) can now be detected non-invasively and characterized in vivo. There is currently a growing body of evidence that photoreceptor and RPE degeneration is indeed slowed down in eyes exhibiting type 1 MNV. However, the proof of a direct protective effect of non-exudative type 1 MNV on visual function in AMD is lacking.

Here, the aim is to demonstrate relative preservation of function along with preserved structure in the immediate vicinity of type 1 MNV, while there is progressive loss of sensitivity and degeneration in the surrounding tissue.

03

Conditions studied

  • Age-Related Macular Degeneration
  • Neovascularization, Choroidal

Keywords

  • Non-exudative type 1 macular neovascularization (MNV)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with AMD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 50 years and older of all ethnicities.
  2. AMD in at least one eye (study eye).
  3. Type 1 macular neovascularization (MNV) in the study eye (to be confirmed by UREAD Reading Center at the Screening and Baseline Visit):

    1. Localized presence of a dense vascular network between Bruch's membrane and retinal pigment epithelium (RPE) on optical coherence tomography angiography (OCT-A) and a double-layer / shallow irregular RPE elevation (SIRE) sign on structural OCT.
    2. MNV lesion does not exceed the image frame of the 9x9 OCT-A scan.
  4. Sufficiently clear ocular media, adequate pupillary dilation, and adequate fixation to permit quality fundus imaging and fundus-controlled perimetry (FCP) testing.
  5. Ability to comply with study protocol timelines.

Exclusion criteria

Exclusion Criteria:

Intermediate AMD group (original cohort): Exclusion criteria 1. - 11. apply. Atrophic AMD and/or previous treatment group (extended cohort): Exclusion criteria 4. - 11. apply.

  1. Atrophy in the study eye defined as:

    • Complete RPE and outer retinal atrophy (cRORA) on OCT with homogeneous choroidal hypertransmission
    • Absence of the RPE band measuring > 250 microns
    • Evidence of overlying photoreceptor degeneration whose features include outer nuclear layer thinning, external limiting membrane loss, and ellipsoid zone or interdigitation zone loss
  2. Signs of exudation in the study eye requiring therapeutic intervention at the discretion of the investigator; NOTE: minimally exudative lesions in the study eye that do not require therapeutic interventions are no exclusion criterion.
  3. Any history of treatment of exudative MNV in the study eye (e.g. type 1, type 2, mixed, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation); NOTE: Non-exudative or minimally exudative type 1 MNV in the study eye, that does not require therapeutic intervention at the discretion of the investigator, is NOT and exclusion criterion; non-exudative or exudative MNV in the fellow eye is not an exclusion criterion. Fellow-eyes may receive treatment of exudative MNV as part of clinical care.
  4. Any disease/disorder other than AMD in the study eye at the time of inclusion (e.g. monogenic retinal diseases, diabetic retinopathy, retinal detachment, previous retinal surgeries, myopic degeneration), uncontrolled glaucoma with IP of higher than 30 mmHg (despite current pharmacological or non-pharmacological treatment) and uveitis.
  5. History of central retinal laser treatment, including photodynamic therapy (PDT) and subthreshold laser treatment for AMD in the study eye.
  6. Cataract surgery in the study eye within the last three months prior to enrollment. YAG capsulotomy in the study eye within the last 2 weeks prior to enrollment.
  7. Current or previous participation in clinical trials investigating drugs or supplements in AMD (except vitamins and minerals), if, in the opinion of the investigator, this affects the outcome of the study.
  8. Current or previous participation (less than 3 months from termination of participation) in clinical trials investigating drugs or supplements in diseases other than AMD, if, in the opinion of the investigator, this affects the outcome of the study.
  9. Any concurrent ocular condition in the study eye (e.g. cataracts) that, in the opinion of the investigator, requires medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition or, if allow to progress untreated, could likely contribute to loss of at least two Snellen equivalent lines of best-corrected visual acuity during the study period.
  10. Concomitant diseases that in the opinion of the investigator would make adherence to the examination schedule difficult of unlikely (e.g. personality disorder, chronic alcoholism, Alzheimer's Disease, drug abuse).
  11. Evidence of significantly uncontrolled concomitant diseases at the discretion of the investigator (e.g. cardiovascular, neurological, pulmonary, renal, hepatic, endocrine gastrointestinal disorder).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
73 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Intermediate AMD group, Original Cohort

  • Cohort 2

    Atrophic AMD and/or previous treatment group, Extended Cohort

06

What researchers measure

Primary outcomes

  1. Mean change in mesopic retinal sensitivity assessed by Fundus-controlled Perimetry (FCP).

    This sensitivity change will be compared between (I) retinal areas colocalizing with non-exudative type 1 MNV (test-point group I) and (II) retinal areas without evidence of MNV (testpoint group II).

    Time frame: At months 36 from baseline.

Secondary outcomes

  1. Changes over time of qualitative and quantitative structural biomarkers for disease progression.

    These changes will be compared between (I) retinal areas co-localizing with non-exudative type 1 MNV and (II) retinal areas without evidence of MNV.

    Time frame: At months 36 from baseline.

  2. Mean change over time in dark-adapted retinal sensitivity assessed by Fundus-controlled Perimetry (FCP).

    This sensitivity change will be compared between (I) retinal areas colocalizing with non-exudative type 1 MNV (test-point group I) and (II) retinal areas without evidence of MNV (testpoint group II).

    Time frame: At months 36 from baseline.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2027, 55 months after the start.

Of 108 non-industry observational studies under Macular Degeneration, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 98. This study's planned 55 months is above that.

Counting every sponsor, half of 164 studies reached it within 44 months; a quarter within 15 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Nov 13, 2023
StartActual
Jan 30, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06125977
Lead sponsor
University of Utah
Responsible party
Monika Fleckenstein (Professor, University of Utah) — Principal investigator
First posted
Nov 13, 2023
Start date
Jan 30, 2023
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Dec 17, 2025

Study contacts

Monika Fleckenstein, MD
principal investigator · University of Utah

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion